Popular Trials
Radioisotope Therapy
Rhenium Re 188 P2045 for Lung Cancer
Recruiting1 awardPhase 1 & 2
Iowa City, Iowa
This trial tests a new drug called Rhenium Re 188 P2045 on lung cancer patients. It aims to find a safe dose and check if it helps reduce tumors. Patients are monitored closely for side effects and tumor response.
MDM2 Inhibitor
Brigimadlin for Solid Cancers
Recruiting1 awardPhase 2
Washington, District of Columbia
This trial is testing a medicine called BI 907828 for adults with advanced cancer in the biliary tract, pancreas, lung, or bladder who have no other treatment options. The medicine is taken as a tablet periodically and works by blocking a protein that helps cancer cells grow.
Chemotherapy
SABR + Pentoxifylline/Vitamin E for Lung Cancer
Recruiting3 awardsPhase 2
Louisville, Kentucky
This trial is testing a combination of a blood flow medication and precise radiation therapy on patients with recurring or new lung cancers. The goal is to see if this combination is safe and effective.
Tremelimumab for Mesothelioma
Recruiting0 awardsPhase 2
Scottsdale, Arizona
This trial is testing a new cancer drug for people with mesothelioma who can't have surgery. 564 people will be enrolled and randomly assigned to either receive the drug or a placebo. There will be follow-ups to check safety and long-term effects.
Popular Filters
Trials for NSCLC Patients
Behavioural Intervention
Decision Coaching for Lung Cancer Screening
Recruiting1 award10 criteria
New Brunswick, New Jersey
This trial is testing whether navigator decision coaching, compared to enhanced usual care, results in better decision making for lung cancer screening, more screenings, and increased adherence to repeat screenings and diagnostic testing. A booster coaching session is also being tested to see if it increases adherence to repeat screenings.
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Boca Raton, Florida
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Platinum-based Chemotherapy
Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer
Recruiting1 awardPhase 3
Mobile, Alabama
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Behavioural Intervention
Communication Intervention for Dementia
Recruiting1 award12 criteria
Seattle, Washington
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Trials for Non-Small Cell Lung Cancer Patients
Behavioural Intervention
Decision Coaching for Lung Cancer Screening
Recruiting1 award10 criteria
New Brunswick, New Jersey
This trial is testing whether navigator decision coaching, compared to enhanced usual care, results in better decision making for lung cancer screening, more screenings, and increased adherence to repeat screenings and diagnostic testing. A booster coaching session is also being tested to see if it increases adherence to repeat screenings.
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Boca Raton, Florida
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Platinum-based Chemotherapy
Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer
Recruiting1 awardPhase 3
Mobile, Alabama
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Behavioural Intervention
Communication Intervention for Dementia
Recruiting1 award12 criteria
Seattle, Washington
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Trials for EGFR Positive Patients
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Boca Raton, Florida
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Monoclonal Antibodies
Amivantamab for Lung Cancer
Recruiting1 awardPhase 1
La Jolla, California
This trial is testing a new drug called Amivantamab alone and with other treatments in patients with advanced lung cancer that hasn't responded to other treatments. The goal is to see if these combinations are safe and effective. The drugs work by stopping cancer cells from growing. Amivantamab targets a rare lung cancer mutation that has been difficult to treat with existing medications.
Janus Kinase (JAK) Inhibitor
Itacitinib + Osimertinib for Lung Cancer
Recruiting1 awardPhase 1 & 2
La Jolla, California
This trial is testing the safety of using two drugs, itacitinib and osimertinib, together. The study focuses on patients with advanced lung cancer that has spread. Itacitinib helps the immune system fight cancer, while osimertinib targets and kills specific cancer cells. Osimertinib is approved for treating a specific type of lung cancer, even in cases where the cancer has become resistant to other treatments.
Trials for PD-L1 Positive Patients
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Boca Raton, Florida
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
PD-1 Inhibitor
Pembrolizumab for Mesothelioma
Recruiting1 awardPhase 2
Chicago, Illinois
This trial is testing how well pembrolizumab works in treating patients with malignant mesothelioma. Pembrolizumab is a monoclonal antibody that works by blocking PD-1, which may stimulate an immune response and kill tumor cells.
Checkpoint Inhibitor
Immunotherapy + Chemotherapy for Lung Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing two different ways to treat lung cancer that has spread, one with two immunotherapy drugs and one with just one immunotherapy drug, compared to just using chemotherapy drugs.
Phase 3 Trials
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Boca Raton, Florida
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Platinum-based Chemotherapy
Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer
Recruiting1 awardPhase 3
Mobile, Alabama
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Tyrosine Kinase Inhibitor
Alectinib vs Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial compares two medications, alectinib and crizotinib, for treating a specific type of advanced lung cancer. The patients have not received any prior treatment for their cancer. Both drugs work by blocking a protein that helps the cancer cells grow. Alectinib has shown superior effectiveness and fewer side effects compared to crizotinib in treating this type of lung cancer.
Proton Beam Therapy
Photon vs Proton Radiation for Non-Small Cell Lung Cancer
Recruiting3 awardsPhase 3
Jacksonville, Florida
This trial is comparing two types of radiation therapy to see which is more effective in treating patients with stage II-IIIB non-small cell lung cancer- proton chemoradiotherapy versus photon chemoradiotherapy.
Alkylating agents
Radiation + Chemotherapy for Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing different radiation therapy regimens to see which is more effective in treating patients with limited-stage small cell lung cancer when given together with chemotherapy.
Trials With No Placebo
Behavioural Intervention
Decision Coaching for Lung Cancer Screening
Recruiting1 award10 criteria
New Brunswick, New Jersey
This trial is testing whether navigator decision coaching, compared to enhanced usual care, results in better decision making for lung cancer screening, more screenings, and increased adherence to repeat screenings and diagnostic testing. A booster coaching session is also being tested to see if it increases adherence to repeat screenings.
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Boca Raton, Florida
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Behavioural Intervention
Communication Intervention for Dementia
Recruiting1 award12 criteria
Seattle, Washington
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.